Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.89 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.64 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.64 |
| ▸ | PTGES | O14684 | 2/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | DLAT | P10515 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 9/20 | 0.52 |
| ▸ | POLL | Q9UGP5 | 3/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7622838 | 0.93 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL878771 | 0.92 | SLC6A2 (0.75) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL25184456 | 0.86 | SLC6A2 (0.85) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL14577497 | 0.85 | SIRT2 (0.86) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL21907266 | 0.85 | SIRT2 (0.86) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL98723 | 0.85 | SIRT2 (0.86) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL12634392 | 0.85 | SIRT2 (0.86) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL14233249 | 0.85 | SIRT2 (0.86) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL15694967 | 0.85 | SIRT2 (0.86) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 | |
| SCHEMBL7871338 | 0.84 | SIRT2 (0.85) | SLC6A2SLC6A4SLC6A3SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375398-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-20250302797-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-10-02 | — | — | US | claimed |
| WO-2024035859-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-02-15 | — | — | WO | claimed |
| WO-2023250110-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-12-28 | — | — | WO | claimed |
| US-11654121-B1 | Combination therapies for the treatment of viral infections | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2023-05-23 | — | — | US | claimed |
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | claimed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | claimed |
| US-20260118894-A1 | PRECISION CONTROL AND CHARACTERIZATION OF DISPENSED SUBSTANCES | ALTOPA INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12524026-B2 | Precision control and characterization of dispensed substances | ALTOPA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-3231446-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2026-01-07 | — | — | EP | disclosed |
| US-20250375398-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4633654-A1 | A SYNERGISTIC COMPOSITION | Toker, Nezihe Filiz (TR) | 2025-10-22 | — | — | EP | disclosed |
| US-20250302797-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3500570-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220242809-A1 | METHODS FOR ISOLATING ESSENTIAL OILS, PHYTOCHEMICALS AND PHARMACEUTICALLY ACTIVE COMPONENTS FROM BIOMASS AND RECONSTITUTING SYNTHETIC FORMULATIONS COMPRISING SAME | ATLAS HEMP COMPANY LLC (US) | 2022-08-04 | — | — | US | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2022153322-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-07-21 | — | — | WO | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | SLC6A2 106/4885SLC6A4 179/4885SLC6A3 162/4885 |
| US-20250302797-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | TNF, MMP8, TSLP | SLC6A2 4018/4885SLC6A4 4235/4885SLC6A3 4213/4885 |
| US-11654121-B1 | Combination therapies for the treatment of viral infections | HAVCR2, EIF2AK2, MAVS | SLC6A2 4006/4885SLC6A4 4071/4885SLC6A3 4376/4885 |
| US-20260118894-A1 | PRECISION CONTROL AND CHARACTERIZATION OF DISPENSED SUBSTANCES | PIEZO1, HTR3D, JAK2 | SLC6A2 341/4885SLC6A4 141/4885SLC6A3 378/4885 |
| US-20250375398-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | SLC6A2 4006/4885SLC6A4 4071/4885SLC6A3 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.